At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are comparing pembrolizumab given after surgery for head and neck cancer with the usual treatment. The usual therapy includes chemotherapy and radiation therapy. The people in this study have head and neck cancer that came back or is a new primary cancer.
-
In this study, researchers are comparing selumetinib plus olaparib to selumetinib alone to treat endometrial or ovarian cancer. People in this study have cancer that came back or keeps growing after treatment. In addition, their cancers have a change (mutation or variant) in a RAS gene.
-
A Phase 2 Study of Pembrolizumab Immunotherapy Plus Standard Treatment in People With Ovarian CancerResearchers want to see if combining pembrolizumab immunotherapy with standard treatment works well for people with ovarian cancer. The people in this study have ovarian cancer with minimal residual disease (MRD). MRD is a small amount of cancer cells remaining in the body after treatment.
- A Phase II Study Assessing Radiation Therapy and Cisplatin Chemotherapy for People with Vulvar Cancer in the Sentinel Lymph Nodes
Full Title Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial (NRG-GY024) (CIRB)
Purpose
When vulvar cancer is removed, surgeons examine the first lymph nodes to which cancer might spread (“sentinel lymph nodes”) to see if they contain cancer cells. If the sentinel lymph nodes contain cancer, the usual treatment is more surgery to remove all of the lymph nodes in the groin, followed by several weeks of radiation therapy to reduce the chance that the cancer will come back. However, removing all of the lymph nodes increases the risk of lymphedema, which causes uncomfortable swelling in the legs, as well as an elevated risk of infection.
In this study, researchers are assessing the use of a slightly higher dose of radiation therapy as well as weekly cisplatin chemotherapy for five weeks after vulvar cancer surgery in people with positive sentinel nodes. They want to see if it is effective for reducing cancer recurrence, without subjecting patients to extensive surgery to remove the groin lymph nodes.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have vulvar cancer that has been surgically removed and has spread to the sentinel lymph nodes.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Mario Leitao at 212-639-3987.
Protocol
21-439Phase
Phase II (phase 2)Disease Status
Newly DiagnosedInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05076942ClinicalTrials.gov
-
The purpose of this study is to assess the safety and effectiveness of the investigational drug repotrectinib in children and young adults with solid tumors that have continued to grow or spread despite treatment. Repotrectinib works by targeting and blocking certain proteins that play a role in cancer growth. Some of these proteins are controlled by the ALK, ROS1, NTRK1, NTRK2, and NTRK3 genes. Researchers also think that combining repotrectinib with the chemotherapy drugs irinotecan and temozolomide may make the treatment more effective.
-
The purpose of this study is to establish a registry to learn about neurocutaneous melanocytosis (NCM) and how people respond to treatments for this rare disease. NCM is seen mainly in children born with large dark-colored areas of skin called cutaneous melanocytic nevi (LCMN). About one in four of children with LCMN also develop NCM.
-
Teclistamab is given as an injection under the skin. The goal is to see if lower doses or stopping treatment will have the same benefit with fewer side effects.
-
The purpose of this study is to find the highest dose of the investigational drug XMT-1660 that can be given safely in people with advanced triple-negative breast cancer (TNBC) that persists despite prior chemotherapy. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
-
The purpose of this study is to find the highest dose of the investigational drug ONO-4685 that can be given safely in people with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL) that came back or continued to grow despite treatment. ONO-4685 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).
-
Skin (dermatologic) conditions are common in people who are receiving or have received cancer treatment. Sometimes the condition is related to the cancer, and sometimes it is related to cancer treatment. In either case, skin conditions can affect a person's quality of life.